RAND's 'Best Guess' On Biosimilars Is $54 Bil. In Cost Savings
Executive Summary
Another rosy report foresees massive savings over the next decade, but RAND acknowledges that many factors will be the true determinants of spending decreases from biosimilars.
You may also be interested in...
How US Can Learn From Biosimilar Implementation In EU
Differences in payer policies have limited the biosimilar opportunity in some EU nations; IMS report points to examples US should replicate or avoid as biosimilars are introduced domestically.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Xpovio Clinical Development Timeline
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.